Liposomes and Extracellular Vesicles As Drug Delivery Systems: A Comparison of Composition, Pharmacokinetics, and Functionalization

Overview

Journal Adv Healthc Mater

Specialties Biomedical Engineering
Biotechnology

Date 2021 Jun 24

PMID 34165909

Citations 96

Authors

Luke van der Koog

Timea B Gandek

Anika Nagelkerke

Affiliations

Soon will be listed here.

Abstract

Over the past decades, lipid-based nanoparticle drug delivery systems (DDS) have caught the attention of researchers worldwide, encouraging the field to rapidly develop improved ways for effective drug delivery. One of the most prominent examples is liposomes, which are spherical shaped artificial vesicles composed of lipid bilayers and able to encapsulate both hydrophilic and hydrophobic materials. At the same time, biological nanoparticles naturally secreted by cells, called extracellular vesicles (EVs), have emerged as promising more complex biocompatible DDS. In this review paper, the differences and similarities in the composition of both vesicles are evaluated, and critical mediators that affect their pharmacokinetics are elucidate. Different strategies that have been assessed to tweak the pharmacokinetics of both liposomes and EVs are explored, detailing the effects on circulation time, targeting capacity, and cytoplasmic delivery of therapeutic cargo. Finally, whether a hybrid system, consisting of a combination of only the critical constituents of both vesicles, could offer the best of both worlds is discussed. Through these topics, novel leads for further research are provided and, more importantly, gain insight in what the liposome field and the EV field can learn from each other.

Citing Articles

A synthetic model of bioinspired liposomes to study cancer-cell derived extracellular vesicles and their uptake by recipient cells.

Lopez R, Ben El Khyat C, Chen Y, Tsering T, Dickinson K, Bustamante P Sci Rep. 2025; 15(1):8430.

PMID: 40069225 PMC: 11897354. DOI: 10.1038/s41598-025-91873-5.

Exosome-based miRNA delivery: Transforming cancer treatment with mesenchymal stem cells.

Balaraman A, Babu M, Afzal M, Sanghvi G, M M R, Gupta S Regen Ther. 2025; 28:558-572.

PMID: 40034540 PMC: 11872554. DOI: 10.1016/j.reth.2025.01.019.

Leveraging nature's nanocarriers: Translating insights from extracellular vesicles to biomimetic synthetic vesicles for biomedical applications.

Chen Y, Douanne N, Wu T, Kaur I, Tsering T, Erzingatzian A Sci Adv. 2025; 11(9):eads5249.

PMID: 40009680 PMC: 11864201. DOI: 10.1126/sciadv.ads5249.

Extracellular Vesicles as Tools for Crossing the Blood-Brain Barrier to Treat Lysosomal Storage Diseases.

Lerussi G, Villagrasa-Araya V, Molto-Abad M, Del Toro M, Pintos-Morell G, Seras-Franzoso J Life (Basel). 2025; 15(1).

PMID: 39860010 PMC: 11766495. DOI: 10.3390/life15010070.

Biodegradable and Stimuli-Responsive Nanomaterials for Targeted Drug Delivery in Autoimmune Diseases.

Parvin N, Joo S, Mandal T J Funct Biomater. 2025; 16(1).

PMID: 39852580 PMC: 11766201. DOI: 10.3390/jfb16010024.

References

Levchenko T, Rammohan R, Lukyanov A, Whiteman K, Torchilin V . Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating. Int J Pharm. 2002; 240(1-2):95-102. DOI: 10.1016/s0378-5173(02)00129-1. View

Takahashi Y, Nishikawa M, Shinotsuka H, Matsui Y, Ohara S, Imai T . Visualization and in vivo tracking of the exosomes of murine melanoma B16-BL6 cells in mice after intravenous injection. J Biotechnol. 2013; 165(2):77-84. DOI: 10.1016/j.jbiotec.2013.03.013. View

Rodallec A, Sicard G, Giacometti S, Carre M, Maia T, Valette M . Tumor uptake and associated greater efficacy of anti-Her2 immunoliposome does not rely on Her2 expression status: study of a docetaxel-trastuzumab immunoliposome on Her2+ breast cancer model (SKBR3). Anticancer Drugs. 2020; 31(5):463-472. DOI: 10.1097/CAD.0000000000000878. View

Zhao J, Santino F, Giacomini D, Gentilucci L . Integrin-Targeting Peptides for the Design of Functional Cell-Responsive Biomaterials. Biomedicines. 2020; 8(9). PMC: 7555639. DOI: 10.3390/biomedicines8090307. View

Rana S, Yue S, Stadel D, Zoller M . Toward tailored exosomes: the exosomal tetraspanin web contributes to target cell selection. Int J Biochem Cell Biol. 2012; 44(9):1574-84. DOI: 10.1016/j.biocel.2012.06.018. View

Kim H, Choi D, Yun S, Choi S, Kang J, Jung J . Proteomic analysis of microvesicles derived from human mesenchymal stem cells. J Proteome Res. 2011; 11(2):839-49. DOI: 10.1021/pr200682z. View

Campbell F, Bos F, Sieber S, Arias-Alpizar G, Koch B, Huwyler J . Directing Nanoparticle Biodistribution through Evasion and Exploitation of Stab2-Dependent Nanoparticle Uptake. ACS Nano. 2018; 12(3):2138-2150. PMC: 5876619. DOI: 10.1021/acsnano.7b06995. View

Gabizon A, Shmeeda H, Barenholz Y . Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003; 42(5):419-36. DOI: 10.2165/00003088-200342050-00002. View

Haraszti R, Didiot M, Sapp E, Leszyk J, Shaffer S, Rockwell H . High-resolution proteomic and lipidomic analysis of exosomes and microvesicles from different cell sources. J Extracell Vesicles. 2016; 5:32570. PMC: 5116062. DOI: 10.3402/jev.v5.32570. View

10.

van der Koog L, Gandek T, Nagelkerke A . Liposomes and Extracellular Vesicles as Drug Delivery Systems: A Comparison of Composition, Pharmacokinetics, and Functionalization. Adv Healthc Mater. 2021; 11(5):e2100639. PMC: 11468589. DOI: 10.1002/adhm.202100639. View

11.

Akita H, Kogure K, Moriguchi R, Nakamura Y, Higashi T, Nakamura T . Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: programmed endosomal escape and dissociation. J Control Release. 2010; 143(3):311-7. DOI: 10.1016/j.jconrel.2010.01.012. View

12.

Flannagan R, Canton J, Furuya W, Glogauer M, Grinstein S . The phosphatidylserine receptor TIM4 utilizes integrins as coreceptors to effect phagocytosis. Mol Biol Cell. 2014; 25(9):1511-22. PMC: 4004599. DOI: 10.1091/mbc.E13-04-0212. View

13.

Arias-Alpizar G, Kong L, Vlieg R, Rabe A, Papadopoulou P, Meijer M . Light-triggered switching of liposome surface charge directs delivery of membrane impermeable payloads in vivo. Nat Commun. 2020; 11(1):3638. PMC: 7371701. DOI: 10.1038/s41467-020-17360-9. View

14.

Sun J, Zhang L, Wang J, Feng Q, Liu D, Yin Q . Tunable rigidity of (polymeric core)-(lipid shell) nanoparticles for regulated cellular uptake. Adv Mater. 2014; 27(8):1402-7. DOI: 10.1002/adma.201404788. View

15.

Dabbah M, Jarchowsky-Dolberg O, Attar-Schneider O, Matalon S, Pasmanik-Chor M, Drucker L . Multiple myeloma BM-MSCs increase the tumorigenicity of MM cells via transfer of VLA4-enriched microvesicles. Carcinogenesis. 2019; 41(1):100-110. DOI: 10.1093/carcin/bgz169. View

16.

Klibanov A, Maruyama K, Torchilin V, Huang L . Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990; 268(1):235-7. DOI: 10.1016/0014-5793(90)81016-h. View

17.

Chi L, Na M, Jung H, Vadevoo S, Kim C, Padmanaban G . Enhanced delivery of liposomes to lung tumor through targeting interleukin-4 receptor on both tumor cells and tumor endothelial cells. J Control Release. 2015; 209:327-36. DOI: 10.1016/j.jconrel.2015.05.260. View

18.

Lin Y, Wu J, Gu W, Huang Y, Tong Z, Huang L . Exosome-Liposome Hybrid Nanoparticles Deliver CRISPR/Cas9 System in MSCs. Adv Sci (Weinh). 2018; 5(4):1700611. PMC: 5908366. DOI: 10.1002/advs.201700611. View

19.

Santiwarangkool S, Akita H, Khalil I, Abd Elwakil M, Sato Y, Kusumoto K . A study of the endocytosis mechanism and transendothelial activity of lung-targeted GALA-modified liposomes. J Control Release. 2019; 307:55-63. DOI: 10.1016/j.jconrel.2019.06.009. View

20.

Lazaro-Ibanez E, Faruqu F, Saleh A, Silva A, Wang J, Rak J . Selection of Fluorescent, Bioluminescent, and Radioactive Tracers to Accurately Reflect Extracellular Vesicle Biodistribution . ACS Nano. 2021; 15(2):3212-3227. PMC: 7905875. DOI: 10.1021/acsnano.0c09873. View